Worth reading
49Recurring
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
30
議決権総数に対する割合（％程度）Wording
Avoiding a definitive answer
How definitive the wording is.This transaction
当社株券等の大規模買付行為等Counterpartyダルトン・インベストメンツ・インク (Dalton Investments, Inc.), ニッポン・アクティブ・バリュー・ファンド・ピーエルシー（Nippon Active Value Fund PLC）, NAVF Select LLC
Disclosing companyASKA Pharmaceutical Holdings Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Date of board resolution2025年８月18日
Consideration and expenses
Type of Consideration現金（市場内取引による株式買付けと記載）
Funding arrangements主として投資一任契約に基づく顧客資産の運用資金を充当する予定。十分な資力があると説明。
Procedures and assumptions
Management structure after acquisition資本政策、報酬制度、株式持ち合い解消、取締役会の構成を含む提案を行う可能性がある。非公開化を決断した場合には、独立系ファイナンシャル・アドバイザーの紹介を含む支援をする意向。
| Item | Details |
|---|---|
| Transaction name | 当社株券等の大規模買付行為等 |
| Counterparty name | ダルトン・インベストメンツ・インク (Dalton Investments, Inc.), ニッポン・アクティブ・バリュー・ファンド・ピーエルシー（Nippon Active Value Fund PLC）, NAVF Select LLC |
| Name of the Subject Company | ASKA Pharmaceutical Holdings Co.,Ltd. |
| Type of Consideration | 現金（市場内取引による株式買付けと記載） |
| Voting rights ownership percentage | After 最大で議決権総数の30％程度となる水準 (before not disclosed) |
| Funding arrangements | 主として投資一任契約に基づく顧客資産の運用資金を充当する予定。十分な資力があると説明。 |
| Date of board resolution | 2025年８月18日 |
| Management structure after acquisition | 資本政策、報酬制度、株式持ち合い解消、取締役会の構成を含む提案を行う可能性がある。非公開化を決断した場合には、独立系ファイナンシャル・アドバイザーの紹介を含む支援をする意向。 |
Items this document does not state (24)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceContract DateExecution Date / Effective DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.当社の対応方針に基づき、取締役会および株主が大規模買付行為等の内容を検討するために必要な情報の提供を求めるため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.